{"id":"dulaglutide-qw","safety":{"commonSideEffects":[{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2108027","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, suppress inappropriate glucagon secretion, and slow gastric emptying.","oneSentence":"GLP-1 receptor agonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:35:40.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07109700","phase":"PHASE2","title":"A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-04-30","conditions":"Type 2 Diabetes","enrollment":216},{"nctId":"NCT05564039","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-30","conditions":"Type 2 Diabetes","enrollment":282},{"nctId":"NCT05659537","phase":"PHASE4","title":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-12-29","conditions":"Diabetes Mellitus, Type 2","enrollment":212},{"nctId":"NCT04515576","phase":"PHASE1","title":"A Study of LY3493269 in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-25","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT05048719","phase":"PHASE2","title":"A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-09-15","conditions":"Type 2 Diabetes","enrollment":383},{"nctId":"NCT04867785","phase":"PHASE2","title":"A Study of LY3437943 in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-05-13","conditions":"Type 2 Diabetes","enrollment":281},{"nctId":"NCT04591626","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT05348122","phase":"PHASE2","title":"A Study of TG103 Injection in Type 2 Diabetes Subjects","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2022-06-15","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT04374578","phase":"","title":"Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-05-08","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT01001104","phase":"PHASE2","title":"A Study of LY2189265 in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT01149421","phase":"PHASE2","title":"A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":755},{"nctId":"NCT00791479","phase":"PHASE2","title":"Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":167},{"nctId":"NCT00630825","phase":"PHASE2","title":"A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-04","conditions":"Diabetes Mellitus Type 2","enrollment":262}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dulaglutide,subcutaneous injection,QW"],"phase":"phase_2","status":"active","brandName":"Dulaglutide,QW","genericName":"Dulaglutide,QW","companyName":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","companyId":"cspc-baike-shandong-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dulaglutide, QW is a glucagon-like peptide 1 receptor agonist used to treat Type 2 Diabetes. It belongs to the drug class of AGONIST and acts on the protein target Glucagon-like peptide 1 receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}